Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 14Tumor-Agnostic 3Thoracic 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Neoplasms by Site 1Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Bronchial Neoplasms 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × napabucasin × Thoracic × Clear all
NCT02826161 2023-11-15

CanStem43L

Sumitomo Pharma America, Inc.

Phase 3 Terminated
4 enrolled 6 charts
Thoracic

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02347917 2022-04-12

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Sumitomo Pharma Co., Ltd.

Phase 1/2 Completed
28 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡